Name: UMIN ID:
Unique ID issued by UMIN | UMIN000014163 |
---|---|
Receipt number | R000016482 |
Scientific Title | Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer |
Date of disclosure of the study information | 2014/07/01 |
Last modified on | 2018/07/01 17:58:59 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2014/06/04 19:28:31 | ||
2 | Update | 2014/06/05 12:48:10 | Institutions |
|
3 | Update | 2014/07/15 17:54:07 | Recruitment status Anticipated trial start date |
|
4 | Update | 2014/07/16 17:22:02 | UMIN ID1 |
|
5 | Update | 2014/07/24 11:55:59 | Institutions |
|
6 | Update | 2015/04/06 14:00:51 | Last name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Organization1 Institutions |
|
7 | Update | 2015/11/16 09:14:49 | Recruitment status |
|
8 | Update | 2018/07/01 17:58:59 | Recruitment status |